Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts.
B82L mouse fibroblasts respond to fibronectin or vitronectin via a syndecan-1-mediated activation of the alphavbeta5 integrin. Cells attached to syndecan-1-specific antibody display only filopodial extension. However, the syndecan-anchored cells extend lamellipodia when the antibody-substratum is supplemented with serum, or low concentrations of adsorbed vitronectin or fibronectin, that are not sufficient to activate the integrin when plated alone. Integrin activation is blocked by treatment with (Arg-Gly-Asp)-containing peptides and function-blocking antibodies that target alphav integrins, as well as by siRNA-mediated silencing of beta5 integrin expression. In addition, alphavbeta5-mediated cell attachment and spreading on high concentrations of vitronectin is blocked by competition with recombinant syndecan-1 ectodomain core protein and by downregulation of mouse syndecan-1 expression by mouse-specific siRNA. Taking advantage of the species-specificity of the siRNA, rescue experiments in which human syndecan-1 constructs are expressed trace the activation site to the syndecan-1 ectodomain. Moreover, both full-length mouse and human syndecan-1 co-immunoprecipitate with the beta5 integrin subunit, but fail to do so if the syndecan is displaced by competition with soluble, recombinant syndecan-1 ectodomain. These results suggest that the ectodomain of the syndecan-1 core protein contains an active site that assembles into a complex with the alphavbeta5 integrin and regulates alphavbeta5 integrin activity.
McQuade
Kyle J
KJ
Graduate Programs in Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, WI 53706, USA.
Beauvais
DeannaLee M
DM
Burbach
Brandon J
BJ
Rapraeger
Alan C
AC
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005353:Fibronectins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006801:Humans; D016023:Integrins / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology; D011509:Proteoglycans / Q000378:metabolism* / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D053668:Syndecan-1; D053667:Syndecans; D019096:Vitronectin / Q000037:antagonists & inhibitors / Q000494:pharmacology
D005353:Fibronectins; D016023:Integrins; D008562:Membrane Glycoproteins; D009842:Oligopeptides; D011509:Proteoglycans; D034741:RNA, Small Interfering; D019030:Receptors, Vitronectin; D011994:Recombinant Proteins; C508241:SDC1 protein, human; C508242:Sdc1 protein, mouse; D053668:Syndecan-1; D053667:Syndecans; D019096:Vitronectin; C064660:integrin alphaVbeta5; C047981:arginyl-glycyl-aspartic acid